Lentiviral Vectors in CAR-T Cell Manufacturing: Biological Principles, Manufacturing Process, and Frontier Development

Ge Yang

doi:10.54097/5qz2zr53

Authors

Ge Yang

DOI:

https://doi.org/10.54097/5qz2zr53

Keywords:

CAR-T, Lentiviral vector, Serum-free suspension, In-vivo generation of CAR-T cells

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy, as the preeminent strategy in immunotherapy, has conferred benefits upon numerous cancer patients. Currently, there are six CAR-T therapies approved by the Food and Drug Administration (FDA), while the China National Medical Products Administration (NMPA) has approved three. The manufacturing process for CAR-T cells (CAR-Ts) entails using lentiviral vectors (LVVs), which are efficacious in transducing functional genes to both dividing and nondividing cells. Also, LVVs exert their capacity to integrate relatively large segments of DNA. Despite this fact, LVV-based CAR-Ts production can prove prohibitively expensive, and the yield of LVV can be further enhanced. In recent years, in-vivo generation of CAR-Ts has attracted significant attention since it stands to eliminate the ex-vivo isolation and activation process for T cells, thereby decreasing the cost and time involved in production. In view of this, this review summarizes the biological principles of LVVs and their manufacturing process, which encompasses lentiviral vector production, T cell isolation and activation, and CAR-Ts production. Additionally, the cutting-edge developments associated with LVVs are outlined herein, offering direction for the production of the next generation of CAR-Ts.

Downloads

Download data is not yet available.

References

Hu Y, Feng J, Gu T, et al. CAR T-cell therapies in China: rapid evolution and a bright future. The Lancet Haematology, 2022, 9(12): e930–e941.

Chen Y-J, Abila B, Mostafa Kamel Y. CAR-T: What Is Next?. Cancers, 2023, 15(3): 663.

Jayaraman J, Mellody M P, Hou A J, et al. CAR-T design: Elements and their synergistic function. EBioMedicine, 2020, 58: 102931.

Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Molecular Therapy - Oncolytics, 2016, 3: 16015.

Jin Z, Maiti S, Huls H, et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Therapy, 2011, 18(9): 849–856.

Niu A, Zou J, Hu X, et al. Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection. Frontiers in immunology, 2023, 14: 1068625.

Deichmann A, Schmidt M. Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy. Current Gene Therapy, 2014, 13(6): 469–477.

Wang D, Tai P W L, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery, 2019, 18(5): 358–378.

Rodrigo S, Senasinghe K, Quazi S. Molecular and therapeutic effect of CRISPR in treating cancer. Medical Oncology, 2023, 40(2): 81.

van Heuvel Y, Schatz S, Rosengarten J F, et al. Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins, 2022, 14(2): 138.

Labbé R P, Vessillier S, Rafiq Q A. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses, 2021, 13(8): 1528.

Meng B, Lever A M. Wrapping up the bad news – HIV assembly and release. Retrovirology, 2013, 10(1): 5.

Marcucci K T, Jadlowsky J K, Hwang W-T, et al. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy, 2018, 26(1): 269–279.

Rout-Pitt N, McCarron A, McIntyre C, et al. Large-scale production of lentiviral vectors using multilayer cell factories. Journal of Biological Methods, 2018, 5(2): e90.

Diaconu I, Ballard B, Zhang M, et al. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Molecular Therapy, 2017, 25(3): 580–592.

Poorebrahim M, Sadeghi S, Fakhr E, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Critical Reviews in Clinical Laboratory Sciences, 2019, 56(6): 393–419.

Wang X, Rivière I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Therapy, 2015, 22(2): 85–94.

Singh H, Huls H, Cooper L J. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunological reviews, 2014, 257(1): 181–190.

Galeano Niño J L, Kwan R Y, Weninger W, et al. Antigen‐specific T cells fully conserve antitumour function following cryopreservation. Immunology & Cell Biology, 2016, 94(4): 411–418.

Comisel R-M, Kara B, Fiesser F H, et al. Lentiviral vector bioprocess economics for cell and gene therapy commercialization. Biochemical Engineering Journal, 2021, 167: 107868.

Ghasemi N, Bandehpour M, Ranjbari J. Optimization of Key Factors in Serum Free Medium for Production of Human Recombinant GM-CSF Using Response Surface Methodology. Iranian Journal of Pharmaceutical Research : IJPR, 2019, 18(Suppl1): 146-156.

Tirapelle M C, Oliveira Lomba A L, Silvestre R N, et al. Transition from serum-supplemented monolayer to serum-free suspension lentiviral vector production for generation of chimeric antigen receptor T cells. Cytotherapy, 2022, 24(8): 850–860.

Gizem Çelebi, Abuzer Alp Yetisgin, Erdem C, et al. A feasibility study of different commercially available serum-free mediums to enhance lentivirus and adeno-associated virus production in HEK 293 suspension cells. Cytotechnology, 2022, 74(6): 635–655.

Bauler M, Roberts J K, Wu C-C, et al. Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media. Molecular Therapy - Methods & Clinical Development, 2020, 17: 58–68.

Radhakrishnan H, Javitz H S, Bhatnagar P. Lentivirus Manufacturing Process for Primary T‐Cell Biofactory Production. Advanced biosystems, 2020, 4(6): 1900288–1900288.

Gopal S, Osborne A E, Hock L, et al. Advancing a rapid, high throughput screening platform for optimization of lentivirus production. Biotechnology journal, 2021, 16(10): 2000621–2000621.

Huckaby J T, Landoni E, Jacobs T M, et al. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. Journal for immunotherapy of cancer, 2021, 9(9): e002737–e002737.

Ruella M, Xu J, Barrett D M, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature medicine, 2018, 24(10): 1499–1503.

Joglekar A V, Sandoval S. Pseudotyped Lentiviral Vectors: One Vector, Many Guises. Human Gene Therapy Methods, 2017, 28(6): 291–301.

Pfeiffer A, Thalheimer F B, Hartmann S, et al. In vivo generation of human CD 19‐ CAR T cells results in B‐cell depletion and signs of cytokine release syndrome. EMBO Molecular Medicine, 2018, 10(11): e9158.

Weidner T, Agarwal S, Perian S, et al. Genetic in vivo engineering of human T lymphocytes in mouse models. Nature Protocols, 2021, 16(7): 3210–3240.

Michels K, Sheih A, Hernandez S A, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. Journal for immunotherapy of cancer, 2023, 11(3): e006292–e006292.

Frank A M, Braun A, Scheib L, et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.. Blood advances, 2020, 4(22): 5702–5715.

Cordes N, Winter N, Kolbe C, et al. Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer. Viruses, 2022, 14(10): 2157–2157.